Cyclacel Pharmaceuticals (CYCC) Proxy Filing summary

Executive summary

• A special meeting of stockholders is scheduled for February 6, 2025, to vote on key proposals affecting capital structure, governance, and financing.

• The meeting will be held virtually, and only stockholders of record as of January 6, 2025, are eligible to vote.

• The agenda includes approval of new share issuances, amendments to corporate documents, and ratification of the external auditor.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock to the interim CEO upon conversion of preferred stock and amend the Series C Preferred Stock Certificate to remove the ownership limitation.

• Proposal 2: Approve issuance of shares in connection with a warrant exchange agreement.

• Proposal 3: Approve a reverse stock split at a ratio between 1:4 and 1:16.

• Proposal 4: Approve an increase in authorized common shares from 100,000,000 to 250,000,000.

• Proposal 5: Approve an amendment to the 2018 Equity Incentive Plan to add 500,000 shares for issuance.

• Proposal 6: Ratify the appointment of Bush & Associates CPA LLP as the independent auditor for 2024.

• Proposal 7: Approve adjournment of the meeting if more time is needed to solicit votes.

Board of directors and corporate governance

• If the proposals pass, the interim CEO could become the largest stockholder, potentially making the company a "controlled company" under Nasdaq rules.

• As a controlled company, requirements for board independence and compensation committee composition would be relaxed.

• The board unanimously recommends voting in favor of all proposals.